Evaluation of biomarker panels for early stage ovarian cancer detection and monitoring for disease recurrence

Gynecologic Oncology

Volumn 110, Issue 3, 2008, Pages 374-382

  Havrilesky, Laura J ^a   Whitehead, Clark M ^b   Rubatt, Jennifer M ^a   Cheek, Robert L ^b   Groelke, John ^b   He, Qin ^b   Malinowski, Douglas P ^b   Fischer, Timothy J ^b   Berchuck, Andrew ^a  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BD Diagnostics Diagnostic Systems TriPath   (United States)

Author keywords

CA125; Early detection; Glycodelin; HE4; MMP7; Monitoring; MUC1; Ovarian cancer; Plau R; Tumor marker

Indexed keywords

BIOLOGICAL MARKER; CA 125 ANTIGEN; HE4 PROTEIN; INHIBIN A; MATRILYSIN; MONOCLONAL ANTIBODY; MUCIN 1; PLACENTA PROTEIN 14; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLAU R PROTEIN; SLPI PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ALGORITHM; AREA UNDER THE CURVE; ARTICLE; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER RECURRENCE; CANCER STAGING; CONTROLLED STUDY; EVALUATION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOASSAY; MAJOR CLINICAL STUDY; MASS SPECTROMETRY; NERVE CELL NETWORK; OVARY CANCER; PRIORITY JOURNAL; ROC CURVE; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; OVARIAN NEOPLASMS; ROC CURVE; TUMOR MARKERS, BIOLOGICAL;

EID: 50149117364     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2008.04.041     Document Type: Article

References (47)

1. Jemal A., Siegel R., Ward E., Murray T., Xu J., Smigal C., et al. Cancer statistics, 2006. CA Cancer J Clin 56 2 (Mar-Apr 2006) 106-130
2. Schink J.C. Current initial therapy of stage III and IV ovarian cancer: challenges for managed care. Sem Oncol 26 1 Suppl 1 (Feb 1999) 2-7
3. Bast Jr. R.C., Feeney M., Lazarus H., Nadler L.M., Colvin R.B., and Knapp R.C. Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest 68 5 (1981) 1331-1337
4. Rustin G.J., Bast Jr. R.C., Kelloff G.J., Barrett J.C., Carter S.K., Nisen P.D., et al. Use of CA-125 in clinical trial evaluation of new therapeutic drugs for ovarian cancer. Clin Cancer Res 10 11 (1 Jun 2004) 3919-3926
5. Jacobs I., Oram D., Fairbanks J., Turner J., Frost C., and Grudzinskas J.G. A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer. Br J Obstet Gynaecol 97 10 (Oct 1990) 922-929
6. van Nagell Jr. J.R., DePriest P.D., Reedy M.B., Gallion H.H., Ueland F.R., Pavlik EJ, et al. The efficacy of transvaginal sonographic screening in asymptomatic women at risk for ovarian cancer. Gynecol Oncol 77 3 (2000) 350-356
7. Menon U., Skates S.J., Lewis S., Rosenthal A.N., Rufford B., Sibley K., et al. Prospective study using the risk of ovarian cancer algorithm to screen for ovarian cancer. J Clin Oncol 23 31 (1 Nov 2005) 7919-7926
8. Bast Jr. R.C. Status of tumor markers in ovarian cancer screening. J Clin Oncol 21 10 Suppl (15 May 2003) 200s-205s
9. Gadducci A., Ferdeghini M., Prontera C., Moretti L., Mariani G., Bianchi R., et al. The concomitant determination of different tumor markers in patients with epithelial ovarian cancer and benign ovarian masses: relevance for differential diagnosis. Gynecol Oncol 44 2 (Feb 1992) 147-154
10. Xu F.J., Ramakrishnan S., Daly L., Soper J.T., Berchuck A., Clarke-Pearson D., et al. Increased serum levels of macrophage colony-stimulating factor in ovarian cancer. Am J Obstet Gynecol 165 5 Pt 1 (Nov 1991) 1356-1362
11. Xu Y., Shen Z., Wiper D.W., Wu M., Morton R.E., Elson P., et al. Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers. JAMA 280 8 (26 Aug 1998) 719-723
12. Kim J.H., Skates S.J., Uede T., Wong K.K., Schorge J.O., Feltmate C.M., et al. Osteopontin as a potential diagnostic biomarker for ovarian cancer. JAMA 287 13 (3 Apr 2002) 1671-1679
13. Healy D.L., Burger H.G., Mamers P., Jobling T., Bangah M., Quinn M., et al. Elevated serum inhibin concentrations in postmenopausal women with ovarian tumors. N Engl J Med 329 21 (18 Nov 1993) 1539-1542
14. Yousef G.M., Polymeris M.E., Yacoub G.M., Scorilas A., Soosaipillai A., Popalis C., et al. Parallel overexpression of seven kallikrein genes in ovarian cancer. Cancer Res 63 9 (1 May 2003) 2223-2227
15. Xu F.J., Yu Y.H., Daly L., Anselmino L., Hass G.M., Berchuck A., et al. OVX1 as a marker for early stage endometrial carcinoma. Cancer 73 7 (1 Apr 1994) 1855-1858
16. Zhang Z., Yu Y., Xu F., Berchuck A., van Haaften-Day C., Havrilesky L.J., et al. Combining multiple serum tumor markers improves detection of stage I epithelial ovarian cancer. Gynecol Oncol 107 3 (Dec 2007) 526-531
17. Shridhar V., Lee J., Pandita A., Iturria S., Avula R., Staub J., et al. Genetic analysis of early-versus late-stage ovarian tumors. Cancer Res 61 15 (1 Aug 2001) 5895-5904
18. Begum F.D., Hogdall C.K., Kjaer S.K., Christensen L., Blaakaer J., Bock J.E., et al. The prognostic value of plasma soluble urokinase plasminogen activator receptor (suPAR) levels in stage III ovarian cancer patients. Anticancer Res 24 3b (May-Jun 2004) 1981-1985
19. Hough C.D., Sherman-Baust C.A., Pizer E.S., Montz F.J., Im D.D., Rosenshein N.B., et al. Large-scale serial analysis of gene expression reveals genes differentially expressed in ovarian cancer. Cancer Res 60 22 (15 Nov 2000) 6281-6287
20. Hough C.D., Cho K.R., Zonderman A.B., Schwartz D.R., and Morin P.J. Coordinately up-regulated genes in ovarian cancer. Cancer Res 61 10 (15 May 2001) 3869-3876
21. Schwartz D.R., Kardia S.L., Shedden K.A., Kuick R., Michailidis G., Taylor J.M., et al. Gene expression in ovarian cancer reflects both morphology and biological behavior, distinguishing clear cell from other poor-prognosis ovarian carcinomas. Cancer Res 62 16 (15 Aug 2002) 4722-4729
22. Drapkin R., von Horsten H.H., Lin Y., Mok S.C., Crum C.P., Welch W.R., et al. Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. Cancer Res 65 6 (15 Mar 2005) 2162-2169
23. Hellstrom I., Raycraft J., Hayden-Ledbetter M., Ledbetter J.A., Schummer M., McIntosh M., et al. The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res 63 13 (1 Jul 2003) 3695-3700
24. Tsukishiro S., Suzumori N., Nishikawa H., Arakawa A., and Suzumori K. Use of serum secretory leukocyte protease inhibitor levels in patients to improve specificity of ovarian cancer diagnosis. Gynecol Oncol 96 2 (Feb 2005) 516-519
25. Sier C.F., Stephens R., Bizik J., Mariani A., Bassan M., Pedersen N., et al. The level of urokinase-type plasminogen activator receptor is increased in serum of ovarian cancer patients. Cancer Res 58 9 (1 May 1998) 1843-1849
26. Robertson D.M., Stephenson T., Pruysers E., Burger H.G., McCloud P., Tsigos A., et al. Inhibins/activins as diagnostic markers for ovarian cancer. Mol Cell Endocrinol 191 1 (31 May 2002) 97-103
27. Kilpatrick K.E., Wring S.A., Walker D.H., Macklin M.D., Payne J.A., Su J.L., et al. Rapid development of affinity matured monoclonal antibodies using RIMMS. Hybridoma 16 4 (Aug 1997) 381-389
28. NCCLS. How to define and determine reference intervals in the clinical laboratory; approved guideline-second edition. NCCLS. 2000(C28-A2 [ISBN 1-56238-406-6]).
29. Sullivan Pepe M. Modeling covariate effects on ROC curves. The statistical evaluation of medical tests for classification and prediction (2003), Oxford University Press 151-163
30. DeLong E.R., DeLong D.M., and Clarke-Pearson D.L. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 44 3 (Sep 1988) 837-845
31. Skates S.J., Horick N., Yu Y., Xu F.J., Berchuck A., Havrilesky L.J., et al. Preoperative sensitivity and specificity for early-stage ovarian cancer when combining cancer antigen CA-125II, CA 15-3, CA 72-4, and macrophage colony-stimulating factor using mixtures of multivariate normal distributions. J Clin Oncol 22 20 (15 Oct 2004) 4059-4066
32. Kozak K.R., Amneus M.W., Pusey S.M., Su F., Luong M.N., Luong S.A., et al. Identification of biomarkers for ovarian cancer using strong anion-exchange ProteinChips: potential use in diagnosis and prognosis. Proc Natl Acad Sci U S A 100 21 (14 Oct 2003) 12343-12348
33. Ardekani A.M., Liotta L.A., and Petricoin III E.F. Clinical potential of proteomics in the diagnosis of ovarian cancer. Expert Rev Mol Diagn 2 4 (2002) 312-320
34. Lancaster J.M., Dressman H.K., Whitaker R.S., Havrilesky L., Gray J., Marks J.R., et al. Gene expression patterns that characterize advanced stage serous ovarian cancers. J Soc Gynecol Investig 11 1 (Jan 2004) 51-59
35. Hibbs K., Skubitz K.M., Pambuccian S.E., Casey R.C., Burleson K.M., Oegema Jr. T.R., et al. Differential gene expression in ovarian carcinoma: identification of potential biomarkers. Am J Pathol 165 2 (Aug 2004) 397-414
36. Meinhold-Heerlein I., Bauerschlag D., Zhou Y., Sapinoso L.M., Ching K., Frierson Jr. H., et al. An integrated clinical-genomics approach identifies a candidate multi-analyte blood test for serous ovarian carcinoma. Clin Cancer Res 13 2 Pt 1 (15 Jan 2007) 458-466
37. El-Shalakany A., Abou-Talib Y., Shalaby H.S., and Sallam M. Preoperative serum inhibin levels in patients with ovarian tumors. J Obstet Gynaecol Res 30 2 (Apr 2004) 155-161
38. Seppala M., Taylor R.N., Koistinen H., Koistinen R., and Milgrom E. Glycodelin: a major lipocalin protein of the reproductive axis with diverse actions in cell recognition and differentiation. Endocr Rev 23 4 (Aug 2002) 401-430
39. Seppala M., Koistinen H., and Koistinen R. Glycodelins. Trends in endocrinology and metabolism. TEM 12 3 (Apr 2001) 111-117
40. Taylor-Papadimitriou J., Burchell J., Miles D.W., and Dalziel M. MUC1 and cancer. Biochimica et Biophysica Acta 1455 2-3 (8 Oct 1999) 301-313
41. Duffy M.J., Bonfrer J.M., Kulpa J., Rustin G.J., Soletormos G., Torre G.C., et al. CA125 in ovarian cancer: European Group on Tumor Markers guidelines for clinical use. Int J Gynecol Cancer 15 5 (Sep-Oct 2005) 679-691
42. Wang F.Q., Smicun Y., Calluzzo N., and Fishman D.A. Inhibition of matrilysin expression by antisense or RNA interference decreases lysophosphatidic acid-induced epithelial ovarian cancer invasion. Mol Cancer Res 4 11 (Nov 2006) 831-841
43. Rosen D.G., Wang L., Atkinson J.N., Yu Y., Lu K.H., Diamandis E.P., et al. Potential markers that complement expression of CA125 in epithelial ovarian cancer. Gynecol Oncol 99 2 (Nov 2005) 267-277
44. Bouchard D., Morisset D., Bourbonnais Y., and Tremblay G.M. Proteins with whey-acidic-protein motifs and cancer. Lancet Oncol 7 2 (Feb 2006) 167-174
45. Zacharski L.R., Memoli V.A., Ornstein D.L., Rousseau S.M., Kisiel W., and Kudryk B.J. Tumor cell procoagulant and urokinase expression in carcinoma of the ovary. J Natl Cancer Inst 85 15 (4 Aug 1993) 1225-1230
46. Scholler N., Crawford M., Sato A., Drescher C.W., O'Briant K.C., Kiviat N., et al. Bead-based ELISA for validation of ovarian cancer early detection markers. Clin Cancer Res 12 7 Pt 1 (1 Apr 2006) 2117-2124
47. Moore R.G., Brown A.K., Miller M.C., Skates S., Allard W.J., Verch T., et al. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol 108 2 (Feb 2008) 402-408.